NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 246)
Posted On: 04/22/2020 3:57:49 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Distinctive Business Model in Exclusive Interview
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its director and CEO Dr. Carl Schwartz was featured in an exclusive interview with NetworkNewsWire (“NNW”). In the interview, Dr. Schwartz discussed Predictive Oncology’s distinctive business model, as well as significant changes management is making to position the company for the future. “Predictive’s major asset is its Helomics subsidiary and its proprietary database of over 150,000 cancer tumors covering over 137 types of cancers, with over 30,000 tumors related to ovarian cancer, which is sort of our specialty. In fact, this is the largest inventory of its kind in the world,” Dr. Schwartz said, explaining that the collection was amassed over the last two decades by physicians sending in cancerous tumors to be tested with the known therapies of the time. “The results of these tests were in turn sent back to the referring physicians to be used as a guide or a reference as desired for treatment of the evaluated tumor. And the evaluated tumor was placed back in the physician’s therapy inventory. That’s how we amassed all these tumors.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its director and CEO Dr. Carl Schwartz was featured in an exclusive interview with NetworkNewsWire (“NNW”). In the interview, Dr. Schwartz discussed Predictive Oncology’s distinctive business model, as well as significant changes management is making to position the company for the future. “Predictive’s major asset is its Helomics subsidiary and its proprietary database of over 150,000 cancer tumors covering over 137 types of cancers, with over 30,000 tumors related to ovarian cancer, which is sort of our specialty. In fact, this is the largest inventory of its kind in the world,” Dr. Schwartz said, explaining that the collection was amassed over the last two decades by physicians sending in cancerous tumors to be tested with the known therapies of the time. “The results of these tests were in turn sent back to the referring physicians to be used as a guide or a reference as desired for treatment of the evaluated tumor. And the evaluated tumor was placed back in the physician’s therapy inventory. That’s how we amassed all these tumors.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)